Roche’s biggest bet in the Alzheimer’s disease space may be its phase 3-stage amyloid asset, but the Swiss pharma is keeping its options open when it comes to targeting tau. Tau is one of two proteins ...
Among the first projects identified under the partnership is a Phase 2 extension study evaluating the safety and efficacy of ...
After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...
Megan Fox's ex-husband Brian Austin Green is opening up about the lesson he learned from their 15-year relationship. "My ex ...
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox ...
Teva Pharmaceuticals (TEVA) secures exclusive global rights to a biosimilar candidate targeting Roche’s (RHHBY) multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results